Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
NCT02730377 on ClinicalTrials.gov · last registry update 2020-07-07
An unusually large phase 4: 1,991 participants, more than double the 75 typical for the stage. The sponsor logged completion for 5 August 2019. Primary outcome, as filed: Time to Inadequate Glycaemic Control. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 1,991
- Started
- 2016-03-28
- Primary completion
- 2019-08-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to Inadequate Glycaemic Control
Conditions studied
Diabetes · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.